Navigation Links
Apollo's human proteins boost stem cell research

itute of Medical Research said that Apollo's range of human cell-expressed proteins exhibit enhanced activity compared with those produced in non-human systems, suggesting that they will be of great value in stem cell research.

"Ultimately this technology could lead to novel treatments for important human diseases such as diabetes and heart disease," he said.

Professor Alan Trounson from Monash University's Immunology and Stem Cell Laboratories and a member of Apollo's Scientific Advisory Panel said the synthesis of proteins from human cells is of vital importance for other areas of research, especially in investigations concerning human diseases.

"Using proteins from non-human sources to research human diseases is not as biologically relevant as using human proteins. Medical research is complex on its own right and removing obstacles will increase the chances of unique discoveries," he said.

Media contact: Andrew Huckel (Wilkinson Media) 02 8001 8818 or 0402 822 622

About Apollo Life Sciences Limited

Apollo Life Sciences (ASX: AOP) is a bio-discovery company that has made major breakthroughs in the areas of drug delivery and expression of proteins from human cells. Apollo's combined technologies are expected to lead to more effective and lower cost therapeutics, compared to first generation protein-based drugs.

www.apollolifesciences.com


'"/>




Page: 1 2

Related medicine technology :

1. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
2. Inovio: DNA delivery technology shows positive human results
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Apollo human proteins boost stem cell research
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 2BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 3Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4Welcome to the Biofuel Age of Flight 12593 1Welcome to the Biofuel Age of Flight 12593 2Welcome to the Biofuel Age of Flight 12593 3Students May Be Solution to Shortage of Medical Professionals 48719 1Students May Be Solution to Shortage of Medical Professionals 48719 2Students May Be Solution to Shortage of Medical Professionals 48719 3Students May Be Solution to Shortage of Medical Professionals 48719 4Hey Governator 21 Dont Terminate Senior Funding 21 48717 1Hey Governator 21 Dont Terminate Senior Funding 21 48717 2Hey Governator 21 Dont Terminate Senior Funding 21 48717 3Hey Governator 21 Dont Terminate Senior Funding 21 48717 4Hey Governator 21 Dont Terminate Senior Funding 21 48717 5
Other Medicine Technology:Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 2Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 3Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 4Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 5Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 6Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 7Gene Therapy Improves Vision in Patients with Congenital Retinal Disease 8BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7